RBC Capital downgraded Avidity Biosciences (RNA) to Sector Perform from Outperform with a price target of $72, up from $61, after Novartis (NVS) announced an agreement to acquire Avidity for $72 per share in cash.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA: